Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008


VIROPHARMA INCORPORATED

Selected Financial Information

Consolidated Statements of Operations:

(in thousands, except Three months ended Twelve months ended

per share data) December 31, December 31,

------------------- -------------------

2007 2006 2007 2006

-------- -------- -------- --------

(unaudited)

Revenue:

Net product sales $47,696 $38,454 $203,770 $166,617

Milestone, license fee and

other revenue - 141 - 564

-------- -------- -------- --------

Revenue 47,696 38,595 203,770 167,181

-------- -------- -------- --------

Costs and Expenses:

Cost of sales (excluding

amortization of product rights) 2,034 2,018 8,934 18,984

Research and development 12,504 3,084 35,869 19,162

Marketing, general and

administrative 12,710 7,093 37,051 24,560

Intangible amortization 1,401 1,342 6,120 5,669

-------- -------- -------- --------

Total costs and expenses 28,649 13,537 87,974 68,375

-------- -------- -------- --------

Operating income 19,047 25,058 115,796 98,806

Net gain on bond repurchase - - - (1,127)

Gain on sale of investments - 1,682 - 1,682

Interest income 7
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
10. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
11. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology 2Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6Amgen to Present at the Thomas Weisel Healthcare Conference 56481 1Amgen to Present at the Thomas Weisel Healthcare Conference 56481 2Antiviral Drugs Should Be Used Cautiously to Fight Flu U S Says 56479 1Antiviral Drugs Should Be Used Cautiously to Fight Flu U S Says 56479 2Antiviral Drugs Should Be Used Cautiously to Fight Flu U S Says 56479 3Caliper Life Sciences to Present at UBS Global Life Sciences Conference 56476 1